Case Study: How Cerba Research Helped Advance a Phase IIB Study in the Middle of a Pandemic and Brexit

How To Improve the Patients Experience in IO Clinical Trials – with the Gustave Roussy Institute

Tech Transfer IFE Reflex Assay China

A Biotech Company in China required our scientific expertise for the Tech Transfer of IFE Reflex Assay on a clinical trial in the Oncology field (Relapsed or Refractory Multiple Myeloma). Cerba Research was not the Biotech’s central or specialty laboratory on the study but brought in for our expertise on the tech transfer.

Download the case study to read more.

Pediatric Phase I/II Clinical Trial on Mucopolysaccharidosis type III (MPSIIIA)

Lab support for a global pediatric trial for the rare genetic neurodegenerative disorder, Mucopolysaccharidosis type III. Cerba Research provided safety testing, sample management, and specialized testing in our histology lab. Read the case study to discover more details.

Pediatric Phase I/II/III Study in X-Linked Myotubular Myopathy (XLMTM)

Lab support for a global pediatric trial for the rare neuromuscular disease, Myotubular Myopathy. Cerba Research provides safety testing, PBMC isolation, biomarkers, and sample management for the clinical trial. Read more on the challenges and solutions in the case study.

Lab Support for the Largest Global Phase III NASH Study to Date

10-Day Study Start & Custom Test Kit Build at the Height of a Pandemic

Cerba Research initiated custom kit building & distribution for an infectious disease study, during the COVID-19 pandemic, in 10 days. A typical timeline is 8 weeks.

Phase 3 Clinical Trial on the Efficacy and Safety of a New Therapy For Post-Exposure Prophylaxis Of COVID-19 And Other Viral Respiratory Illnesses

Phase 2c Clinical Trial on the Efficacy, Safety and Tolerability of Drug-Sensitive Smear-Positive Pulmonary Tuberculosis (DS TB) Treatment

Phase 3 Clinical Trial on the Safety and Efficacy Of Combination Therapies in Patients with Either Extensively Drug-Resistant Tuberculosis (XDR-TB), Pre-XDR-TB Or Treatment Intolerant Or Non- Responsive Multi-Drug Resistant Tuberculosis (MDR-TB)